12,372 trials
Relapsing-Remitting Multiple Sclerosis
Primary: Adjusted Annualized Relapse Rate (ARR) — 0.393; 0.216 relapses per person-years — p=< 0.0001
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving Sustained Remission Rate At Week 104 — 85.8; 83.5; 44.4 Percentage of participants — p=< 0.001
Primary Myelofibrosis (MF)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 50; 46; 12; 5 Participants
Breast Cancer
Primary: Ipsilateral Breast Tumor Recurrence — 1.4; 1.5 percentage of participants
Hemorrhage
Primary: Hemostasis at the Target Bleeding Site (TBS) at 4-minutes Following Randomization — 48; 24 participants with hemostatic success — p=<.0001
Hodgkin's Lymphoma
Primary: Number of Participants With Adverse Events — 26; 11 Participants
Progressive Keratoconus
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -1.7; 0.6 diopters
Low Back Pain
Primary: Change in Visual Analogue Scale Score for Pain Over 12 Weeks (OMT vs Sham OMT) — 40; 20 participants — p=0.007
Homozygous Familial Hypercholesterolemia (HoFH)
Primary: LDL-Cholesterol (mg/dL) — 396.0; 481.4 mg/dL — p=0.005
Chronic Hepatitis C Infection · Compensated Cirrhosis
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment — 100 percentage of participants
Chronic Hepatitis C Virus (HCV) Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment — 100 percentage of participants
Fabry Disease
Primary: Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium — 18.8; 33.3; 75; 80 Percentage of participants
Hepatitis C, Chronic
Primary: Percentage of Participants in Korea and Taiwan With Sustained Virologic Response (SVR) at Follow-Up Week 24 - Full Analysis Set (FAS) Population — 60.90; 26.15…
Breast Cancer
Primary: Overall Survival — 2.14; 2.00 years
Peroxisome Biogenesis Disorders
Primary: Peroxisome Biochemical Functions as Measured by Plasma Very Long Chain Fatty Acid — 0.180; 0.188 ratio